C2N Diagnostics to Report Results of APTUS™-Aβ Blood Test for Alzheimer’s Disease Brain Pathology

C2N Diagnostics today announced that it will present data from a proof-of-concept study of its APTUS™-Aβ blood test on Friday December 6th at 5 PM at the Late Breaking session of Clinical Trials in Alzheimer’s Disease 2019 conference (Hilton Bayfront in San Diego, CA). The APTUS™-Aβ blood test measures amyloid beta proteins in blood samples and can be used to predict presence of Alzheimer’s pathology in a patient’s brain. C2N was granted Breakthrough Device Designation from the FDA for this technology and development of the test is partially funded by a FastTrack Small Business Innovation Research grant from the National Institute of Ageing at the NIH as well as a grant from the BrightFocus Foundation.

About C2N Diagnostics

C2N Diagnostics, LLC (www.c2ndiagnostics.com) was formed by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, MO and LifeTech Research, a technology research and venture development firm. C2N is commercializing a suite of biomarker tests to enable drug development and early detection of debilitating neurodegenerative disorders before symptom onset. The company's products include the SILK-Aβ® Assay, which rely upon stable isotope labeling and mass spectrometry for the measurement of in vivo metabolism, and quantitation of brain derived proteins. The company has leveraged this expertise in mass spectrometry and amyloid proteins to develop the APTUS™-Aβ blood test, a highly sensitive method for measuring amyloid beta peptides in blood samples. The APTUS™ platform can be used to predict brain amyloid pathology from a single blood sample. In early 2019, C2N was granted Breakthrough Device Designation for the APTUS™-Aβ test from the US-FDA for this technology, and the company is working towards clinical validation and commercialization of the test. In addition to the diagnostic efforts, C2N has developed a portfolio of anti-tau antibodies (including ABBV-8E12) for the treatment of Alzheimer’s Disease and other neurological disorders, and in March 2015 C2N formed a global partnership with AbbVie to develop and commercialize these antibodies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005913/en/